BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 15498502)

  • 1. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo.
    Shin JM; Sachs G
    Biochem Pharmacol; 2004 Dec; 68(11):2117-27. PubMed ID: 15498502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.
    Besancon M; Simon A; Sachs G; Shin JM
    J Biol Chem; 1997 Sep; 272(36):22438-46. PubMed ID: 9278394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo.
    Shin JM; Homerin M; Domagala F; Ficheux H; Sachs G
    Biochem Pharmacol; 2006 Mar; 71(6):837-49. PubMed ID: 16405921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of acid secretion following treatment with proton pump inhibitors.
    Shin JM; Sachs G
    Gastroenterology; 2002 Nov; 123(5):1588-97. PubMed ID: 12404233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole.
    Nishioka K; Nagao T; Urushidani T
    Biochem Pharmacol; 1999 Oct; 58(8):1349-59. PubMed ID: 10487539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Proton pump inhibitors: Pantoprazole].
    Takeuchi K; Hase S
    Nihon Rinsho; 2002 Feb; 60 Suppl 2():655-60. PubMed ID: 11979865
    [No Abstract]   [Full Text] [Related]  

  • 7. Proton pump inhibitors: new drugs and indications.
    Mears JM; Kaplan B
    Am Fam Physician; 1996 Jan; 53(1):285-92. PubMed ID: 8546054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells.
    Yeo M; Kim DK; Kim YB; Oh TY; Lee JE; Cho SW; Kim HC; Hahm KB
    Clin Cancer Res; 2004 Dec; 10(24):8687-96. PubMed ID: 15623654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pantoprazole treatment does not invoke anti-inflammatory properties in vivo.
    Becker TL; Maróstica M; Ribeiro ML; de Mendonça S; Gambero A; Pedrazzoli J
    Int Immunopharmacol; 2004 Aug; 4(8):1051-7. PubMed ID: 15222979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
    Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
    Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors.
    Masubuchi N; Hakusui H; Okazaki O
    Drug Metab Dispos; 1997 May; 25(5):584-9. PubMed ID: 9152597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The basis of differentiation of PPIs.
    Sachs G; Shin JM
    Drugs Today (Barc); 2004 Mar; 40 Suppl A():9-14. PubMed ID: 15190382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of pantoprazole drug interactions in man.
    Steinijans VW; Huber R; Hartmann M; Zech K; Bliesath H; Wurst W; Radtke HW
    Int J Clin Pharmacol Ther; 1994 Aug; 32(8):385-99. PubMed ID: 7981922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
    Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
    Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ["Mirror, mirror on the wall which is the best proton pump inhibitor of all?"].
    Labenz J; Petersen KU; Rösch W; Koelz HR
    Z Gastroenterol; 2003 Nov; 41(11):1123. PubMed ID: 14648385
    [No Abstract]   [Full Text] [Related]  

  • 16. Selective inhibition of the gastric H+,K(+)-ATPase by omeprazole and related compounds.
    Lorentzon P; Bayati A; Lee H; Andersson K
    Ann N Y Acad Sci; 1997 Nov; 834():592-9. PubMed ID: 9405870
    [No Abstract]   [Full Text] [Related]  

  • 17. [Recent topics on important drugs for H. pylori eradication: Pantoprazole sodium].
    Okazaki K; Mori S; Tahashi K
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():354-60. PubMed ID: 16363559
    [No Abstract]   [Full Text] [Related]  

  • 18. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.
    Dammann HG; Burkhardt F
    Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1277-82. PubMed ID: 10563540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.
    Katashima M; Yamamoto K; Tokuma Y; Hata T; Sawada Y; Iga T
    Eur J Drug Metab Pharmacokinet; 1998; 23(1):19-26. PubMed ID: 9625268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo cytochrome P 450 interactions of the newly developed H+/K(+)-ATPase inhibitor pantoprazole (BY 1023/SK&F 96022) compared to other antiulcer drugs.
    Hanauer G; Graf U; Meissner T
    Methods Find Exp Clin Pharmacol; 1991; 13(1):63-7. PubMed ID: 1651432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.